Non-covalent btk inhibitors—the new btkids on the block for b-cell malignancies

Research output: Contribution to journalReview articlepeer-review

24 Citations (Scopus)


The B-cell receptor signalling pathway plays a critical role in development of B-cell malignancies, and the central role of Bruton’s tyrosine kinase (BTK) activation in this pathway provides compelling rationale for BTK inhibition as a therapeutic strategy for these conditions. Covalent BTK inhibitors (BTKi) have transformed the treatment landscape of B-cell malignancies, but adverse events and treatment resistance have emerged as therapeutic challenges, with the majority of patients eventually discontinuing treatment due to toxicity or disease progression. Non-covalent BTKi have alternative mechanisms of binding to BTK than covalent BTKi, and therefore offer a therapeutic alternative for patients with B-cell malignancies, including those who have been intolerant to, or experienced disease progression during treatment with a covalent BTKi. Here, we summarise the clinical data, adverse events and mechanisms of resistance observed with covalent BTKi and describe the emerging data for non-covalent BTKi as a novel treatment for B-cell malignancies.

Original languageEnglish
Article number764
JournalJournal of Personalized Medicine
Issue number8
Publication statusPublished - Aug 2021


Dive into the research topics of 'Non-covalent btk inhibitors—the new btkids on the block for b-cell malignancies'. Together they form a unique fingerprint.

Cite this